Slovenija - slovenščina - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

glaxosmithkline consumer healthcare (uk) trading limited - fenilefrin; gvaifenezin; paracetamol - kapsula, trda - fenilefrin 5 mg / 1 kapsula  gvaifenezin100 mg / 1 kapsula  paracetamol500 mg / 1 kapsula; gvaifenezin 100 mg / 1 kapsula  paracetamol500 mg / 1 kapsula; paracetamol 500 mg / 1 kapsula - paracetamol, kombinacije brez psiholeptikov

Slovenija - slovenščina - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

glaxosmithkline consumer healthcare (uk) trading limited - fenilefrin, gvaifenezin, paracetamol - kapsula, trda - fenilefrin 5 mg / 1 kapsula; gvaifenezin 100 mg / 1 kapsula; paracetamol 500 mg / 1 kapsula - paracetamol, kombinacije brez psiholeptikov

Slovenija - slovenščina - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

glaxosmithkline consumer healthcare (uk) trading limited - fenilefrin; gvaifenezin; paracetamol - prašek za peroralno raztopino - fenilefrin 10 mg / 1 g  gvaifenezin200 mg / 1 g  paracetamol1000 mg / 1 g; gvaifenezin 200 mg / 1 g  paracetamol1000 mg / 1 g; paracetamol 1000 mg / 1 g - paracetamol, kombinacije brez psiholeptikov

Slovenija - slovenščina - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

vetoquinol biowet sp -

Slovenija - slovenščina - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

oncogenerika sp. z.o.o., - letrozol - filmsko obložena tableta - letrozol 2,5 mg / 1 tableta - letrozol

Evropska unija - slovenščina - EMA (European Medicines Agency)

sanofi winthrop industrie - dupilumab - dermatitis, atopic; prurigo; esophageal diseases; asthma; sinusitis - sredstva za dermatitis, razen kortikosteroidov - atopic dermatitisadults and adolescentsdupixent is indicated for the treatment of moderate-to-severe atopic dermatitis in adults and adolescents 12 years and older who are candidates for systemic therapy. children 6 months to 11 years of agedupixent is indicated for the treatment of severe atopic dermatitis in children 6 months to 11 years old who are candidates for systemic therapy. asthmaadults and adolescentsdupixent is indicated in adults and adolescents 12 years and older as add-on maintenance treatment for severe asthma with type 2 inflammation characterised by raised blood eosinophils and/or raised fraction of exhaled nitric oxide (feno), see section 5. 1, who are inadequately controlled with high dose inhaled corticosteroids (ics) plus another medicinal product for maintenance treatment. children 6 to 11 years of agedupixent is indicated in children 6 to 11 years old as add-on maintenance treatment for severe asthma with type 2 inflammation characterised by raised blood eosinophils and/or raised fraction of exhaled nitric oxide (feno), who are inadequately controlled with medium to high dose inhaled corticosteroids (ics) plus another medicinal product for maintenance treatment. chronic rhinosinusitis with nasal polyposis (crswnp)dupixent is indicated as an add-on therapy with intranasal corticosteroids for the treatment of adults with severe crswnp for whom therapy with systemic corticosteroids and/or surgery do not provide adequate disease control. prurigo nodularis (pn)dupixent is indicated for the treatment of adults with moderate-to-severe prurigo nodularis (pn) who are candidates for systemic therapy. eosinophilic esophagitis (eoe)dupixent is indicated for the treatment of eosinophilic esophagitis in adults and adolescents 12 years and older, weighing at least 40 kg, who are inadequately controlled by, are intolerant to, or who are not candidates for conventional medicinal therapy.

Evropska unija - slovenščina - EMA (European Medicines Agency)

teva b.v. - salmeterol, fluticasone propionat - pulmonary disease, chronic obstructive; asthma - zdravila za obstruktivne pljučne bolezni, - airexar spiromax je indicirano za uporabo pri odraslih, starih 18 let in več, samo. asthmaairexar spiromax is indicated for the regular treatment of patients with severe asthma where use of a combination product (inhaled corticosteroid and long-acting β2 agonist) is appropriate:- patients not adequately controlled on a lower strength corticosteroid combination productor- patients already controlled on a high dose inhaled corticosteroid and long-acting β2 agonist. kronična obstruktivna pljučna bolezen (kopb)airexar spiromax je primerna za simptomatsko zdravljenje bolnikov s kopb s fev1.

Slovenija - slovenščina - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

pliva ljubljana d.o.o., ljubljana - promazin - obložena tableta - promazin 22,1547 mg / 1 tableta - promazin

Slovenija - slovenščina - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

pliva ljubljana d.o.o., ljubljana - promazin - obložena tableta - promazin 88,62 mg / 1 tableta - promazin

Evropska unija - slovenščina - EMA (European Medicines Agency)

novartis europharm ltd - ofatumumab - levkemija, limfocitna, kronična, b-celica - monoklonska protitelesa - predhodno nezdravljenih kronično limfocitno levkemijo (cll): arzerra v kombinaciji z chlorambucil ali bendamustine je indiciran za zdravljenje bolnikov z cll, ki še niso prejeli pred terapijo in ki niso upravičeni do fludarabine, ki temelji terapija. relapsed cll: arzerra je navedeno v kombinaciji z fludarabine in ciklofosfamid za zdravljenje odraslih bolnikov z relapsed cll. ognjevzdržni cll: arzerra je primerna za zdravljenje cll pri bolnikih, ki so utrjene, da fludarabine in alemtuzumab.